

INTRAVASCULAR DELIVERY OF METHYLPREDNISOLONE

ABSTRACT OF THE DISCLOSURE

The present invention provides improved devices and methods for minimizing
5 and/or inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the
present invention provides luminal prostheses which allow for programmed and controlled
methylprednisolone delivery with increased efficacy to selected locations within a patient's
vasculature to inhibit restenosis. An intraluminal delivery prosthesis may comprise an
expansible structure and means on or within the structure for releasing methylprednisolone
10 into the body lumen to inhibit smooth muscle cell proliferation.

PA 3126298 v1